Year: 2025
Type: article
Abstract: Clascoterone cream 1% is an androgen receptor inhibitor approved for the topical treatment of acne vulgaris (AV) in patients 12 years of age and older.This article summarizes data from a poster presentation on clascoterone cream 1% at the 2024 Fall Clinical Dermatology Conference, held in October 2024 in Las Vegas, USA.In this study, clascoterone cream 1% significantly reduced facial sebum production over 12 weeks of treatment in patients with mild-to-moderate acne.This marks the first clinical study to show an impact of clascoterone on sebum production and provides further evidence of its efficacy as a topical option for treating androgen-stimulated excess sebum production in male and female patients with AV.
Author: Helen Boreham
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Sun Pharma
OpenAlex ID: W4410029511